{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:46:06Z","timestamp":1792590366811,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016916","name":"Royal Marsden Cancer Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016916","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euros.2026.08.003","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:58:43Z","timestamp":1787259523000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparative Assessment of METastasis Reporting and Data System for Prostate Cancer Versus Prostate Cancer Clinical Trials Working Group 3 Criteria in Assessing Treatment Response in Patients with Metastatic Castration-resistant Prostate Cancer"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0495-7462","authenticated-orcid":false,"given":"Luca","family":"Russo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ossian","family":"Longoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bottazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Biscombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Withey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Avesani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Abramovicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Blackledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"D\u2019Erme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Russell-Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Paschalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evis","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dow-Mu","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.08.003_b0005","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.euros.2024.06.010","article-title":"Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic Castration-resistant prostate cancer patients","volume":"66","author":"Wenzel","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euros.2026.08.003_b0010","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.08.003_b0015","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200195","article-title":"Meta-analysis of candidate surrogate end points in advanced prostate cancer","volume":"2","author":"Gharzai","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.euros.2026.08.003_b0020","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.euo.2019.06.008","article-title":"Early post-treatment prostate-specific antigen at 4 weeks and abiraterone and enzalutamide treatment for advanced prostate cancer: an international collaborative analysis","volume":"3","author":"Rescigno","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2026.08.003_b0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/pcan.2016.71","article-title":"Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL","volume":"20","author":"Bryce","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euros.2026.08.003_b0030","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ccell.2017.09.003","article-title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling","volume":"32","author":"Bluemn","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euros.2026.08.003_b0035","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2018.01.043","article-title":"Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer","volume":"74","author":"Mahal","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.003_b0040","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1007\/s12094-022-02784-0","article-title":"Review of imaging techniques for evaluating morphological and functional responses to the treatment of bone metastases in prostate and breast cancer","volume":"24","author":"Orcajo-Rincon","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.euros.2026.08.003_b0045","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/sj.bjc.6605334","article-title":"Imaging metastatic bone disease from carcinoma of the prostate","volume":"101","author":"Messiou","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euros.2026.08.003_b0050","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000943","article-title":"Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer","volume":"5","author":"Rao","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.euros.2026.08.003_b0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2019.10.030","article-title":"Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: the CATS international database","volume":"125","author":"Delanoy","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euros.2026.08.003_b0060","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.euo.2022.05.003","article-title":"EAU-EANM consensus statements on the role of prostate-specific membrane antigen positron emission tomography\/computed tomography in patients with prostate cancer and with respect to [177Lu]Lu-PSMA radioligand therapy","volume":"5","author":"Fanti","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2026.08.003_b0065","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.2967\/jnumed.124.268020","article-title":"Intrapatient intermetastatic heterogeneity determined by triple-tracer PET imaging in mCRPC patients and correlation to survival: the 3TMPO cohort study","volume":"65","author":"Pouliot","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euros.2026.08.003_b0070","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","article-title":"Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer","volume":"76","author":"Paschalis","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.003_b0075","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.08.003_b0080","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3390\/cancers16142531","article-title":"Multiparametric whole-body MRI: a game changer in metastatic prostate cancer","volume":"16","author":"Cattabriga","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euros.2026.08.003_b0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40644-020-00350-x","article-title":"Whole-body magnetic resonance imaging (WB-MRI) reporting with the metastasis reporting and data system for prostate cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels","volume":"20","author":"Pricolo","year":"2020","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.euros.2026.08.003_b0090","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s00256-024-04723-2","article-title":"Present and future of whole-body MRI in metastatic disease and myeloma: how and why you will do it","volume":"53","author":"Lecouvet","year":"2024","journal-title":"Skelet Radiol"},{"key":"10.1016\/j.euros.2026.08.003_b0095","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1007\/s00330-025-11564-7","article-title":"Influence of imaging method on fat fraction estimation for assessing bone marrow in metastatic prostate cancer","volume":"35","author":"Azma","year":"2025","journal-title":"Eur Radiol"},{"key":"10.1016\/j.euros.2026.08.003_b0100","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20230240","article-title":"Relative fat fraction of malignant bone lesions from breast cancer, prostate cancer and myeloma are significantly lower than normal bone marrow and shows excellent interobserver agreement","volume":"96","author":"Castagnoli","year":"2023","journal-title":"Br J Radiol"},{"key":"10.1016\/j.euros.2026.08.003_b0105","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.eururo.2024.05.004","article-title":"Whole-body diffusion-weighted magnetic resonance imaging for assessment of the bone response rate in patients with metastatic hormone-sensitive prostate cancer receiving enzalutamide","volume":"86","author":"Dalla Volta","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.003_b0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","article-title":"METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer","volume":"71","author":"Padhani","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.003_b0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s40644-023-00644-w","article-title":"Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer","volume":"23","author":"Donners","year":"2023","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.euros.2026.08.003_b0120","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1007\/s00330-025-12089-9","article-title":"ESUR: opportunities for PSMA-PET\/CT and whole-body MRI in advanced prostate cancer","volume":"36","author":"Woo","year":"2025","journal-title":"Eur Radiol"},{"key":"10.1016\/j.euros.2026.08.003_b0125","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euros.2026.08.003_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v080.i01","article-title":"brms: an R package for Bayesian multilevel models using Stan","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J Stat Soft"},{"key":"10.1016\/j.euros.2026.08.003_b0135","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1207\/S15328031US0104_02","article-title":"Partitioning variation in multilevel models","volume":"1","author":"Goldstein","year":"2002","journal-title":"Underst Stat"},{"key":"10.1016\/j.euros.2026.08.003_b0140","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.eururo.2024.02.016","article-title":"Whole-body magnetic resonance imaging as a treatment response biomarker in castration-resistant prostate cancer with bone metastases: the iPROMET clinical trial","volume":"86","author":"Garcia-Ruiz","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.003_b0145","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.euo.2024.10.009","article-title":"Value of whole-body magnetic resonance imaging using the MET-RADS-P criteria for assessing the response to intensified androgen deprivation therapy in metastatic hormone-naive and castration-resistant prostate cancer","volume":"8","author":"Van Damme","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2026.08.003_b0150","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920987654","article-title":"Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging","volume":"13","author":"Conteduca","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.euros.2026.08.003_b0155","doi-asserted-by":"crossref","first-page":"7564","DOI":"10.1007\/s00330-024-10864-8","article-title":"Evaluating prostate cancer bone metastases response with whole-body MRI: what we know and still need to know","volume":"34","author":"Padhani","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.euros.2026.08.003_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.772530","article-title":"Bone metastases are measurable: the role of whole-body MRI and positron emission tomography","volume":"11","author":"Oprea-Lager","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.euros.2026.08.003_b0165","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/RLI.0000000000000415","article-title":"Multiparametric magnetic resonance imaging of prostate cancer bone disease: correlation with bone biopsy histological and molecular features","volume":"53","author":"Perez-Lopez","year":"2018","journal-title":"Invest Radiol"},{"key":"10.1016\/j.euros.2026.08.003_b0170","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2214\/AJR.21.27323","article-title":"Head-to-head comparison of 68Ga-PSMA-11 PET\/CT and 99mTc-MDP bone scintigraphy for the detection of bone metastases in patients with prostate cancer: a meta-analysis","volume":"219","author":"Zhao","year":"2022","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.euros.2026.08.003_b0175","doi-asserted-by":"crossref","first-page":"678","DOI":"10.2967\/jnumed.119.233817","article-title":"Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: the PSMA PET progression criteria","volume":"61","author":"Fanti","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euros.2026.08.003_b0180","first-page":"1651","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euros.2026.08.003_b0185","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s00259-017-3780-7","article-title":"Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging","volume":"44","author":"Sheikhbahaei","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euros.2026.08.003_b0190","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00259-024-06891-8","article-title":"Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-\/[18F]F-PSMA-11\/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET\/CT: a pilot study","volume":"52","author":"Pabst","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euros.2026.08.003_b0195","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.08.003_b0200","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3390\/diagnostics12081981","article-title":"Radiotherapy to the primary tumor: the first step of a tailored therapy in metastatic prostate cancer","volume":"12","author":"Ferro","year":"2022","journal-title":"Diagnostics (Basel)"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326006695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326006695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:26:58Z","timestamp":1790825218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168326006695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":40,"alternative-id":["S2666168326006695"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.08.003","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Assessment of METastasis Reporting and Data System for Prostate Cancer Versus Prostate Cancer Clinical Trials Working Group 3 Criteria in Assessing Treatment Response in Patients with Metastatic Castration-resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}